3-Methyladenine (3-MA)

For research use only.

Catalog No.S2767 Synonyms: NSC 66389

456 publications

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's 3-Methyladenine (3-MA) has been cited by 456 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D M3WxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXB[oo{dU1? NUCxV2pSOmh? NW\0UnRpTE2VTx?= NVvQd4ZPemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= NWf4eHIyOjV5MU[1OlE>
A549  M2\4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ZcJU{dU1? NEHofZkzcA>? NFPKUYVFVVOR M4fSTpJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? NH3ibZkzPTdzNkW2NS=>
95D NGP2bZBCeG:ydH;zbZMhSXO|YYm= MXe1cW0> M2D4NlJp MX7EUXNQ Mmj3bY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq MlXnNlU4OTZ3NkG=
A549  M3nGXWFxd3C2b4Ppd{BCe3OjeR?= MUK1cW0> MWeybC=> M3TyNGROW09? NYixZlJUcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo M{\hNVI2PzF4NU[x
NBL-W-S  NEi5N41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ae2cydU1? M1v2W|Zp M3n1SYVvcGGwY3XzJGdCVlRvNkGgeI95cWOrdIm= NEWxR|czPTN{M{KyNi=>
NBL-W-S  MX;BdI9xfG:|aYOgRZN{[Xl? NHnWfngydU1? NF;kSI43cA>? NVzOd2FScW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhT0GQVD22NS=> MWqyOVMzOzJ{Mh?=
A2780cp  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixcW0> NUPQOnZyOWh? MlrSbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> M3nNZ|I2OzJ{Nkm0
A549  MYfGeY5kfGmxbjDBd5NigQ>? NWD0WHFYPW2P NGjmT2MzcA>? Mkj0d5VxeHKnc4Pld{BUWENiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhVEN|LVnJ NGDzdnczPTJ6NU[yPC=>
H157 MkX6SpVv[3Srb36gRZN{[Xl? M1r5W|VuVQ>? MX2ybC=> MV3zeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= NWrxd483OjV{OEW2Nlg>
MDR MVLBdI9xfG:|aYOgRZN{[Xl? MlO3NVBuVQ>? NVO1dok6Pmh? MXjzeJJmdme2aHXud{B1cGVicH;3[ZIhd2ZiYX70bYNidmOncjDkdpVoew>? NX\Jfo5DOjVyMUm3NFE>
HT-29  M1LhO2Fxd3C2b4Ppd{BCe3OjeR?= M4\WfFFuVQ>? NVT4U49wPDiq NX7n[Gt5TE2VTx?= NWHxTJp7\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? M13GNFI1QDR{MUW4
Microglia  M1S4N2Fxd3C2b4Ppd{BCe3OjeR?= NWrTS|ZyPW2P M4q0fVI1cA>? MnHQ[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo M4rCXVI1QDF6NkCx
A2780cp NV7mUXV2SXCxcITvd4l{KEG|c3H5 MmDXNk42dU1? MnX1NYg> Ml;q[IRJOk9? NIPTblBmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MlXyNlQ5OTd7NE[=
HepG2 MW\GeY5kfGmxbjDBd5NigQ>? NWDwZXJtPW2P NXLoXFdQPGh? Mkm2bY5kemWjc3XzJGhNKHKnbHXhd4U> MnrtNlQ4OTN3OEe=
A549 NIDtfZhCeG:ydH;zbZMhSXO|YYm= MkHpOY1O NXnRN5Q2PDiq NUnNeXQz\GWlcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHyg[IVifGhiYX7kJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKGOjc4Dhd4UuOyxiQnXjcIlvNTFiYX7kJGxEOy2LSR?= MlHkNlQ4ODZ|MEO=
U2OS NF3odYhCeG:ydH;zbZMhSXO|YYm= M13jO|ExdU1? NXTJSYkxOjSq NGLyb45qdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? MnTaNlQ3OzlyMUO=
Saos-2 NUC0NpN1SXCxcITvd4l{KEG|c3H5 Mn\2NVBuVQ>? NH3QNHQzPGh? NYP4RYVYcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 NUTIUm5jOjR4M{mwNVM>
A549 MnrXRZBweHSxc3nzJGF{e2G7 NIO0[XAyOG2P NH\5XWE1QGh? MojvZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? MXyyOFYzPjd{Mh?=
HCT116  MU\BdI9xfG:|aYOgRZN{[Xl? NXuySItWPW2P MYGyOIg> NETONHlmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6= NYjteotlOjR4Mk[1NlI>
HGC-27 Mo\WSpVv[3Srb36gRZN{[Xl? NHW5fpYyOG2P Mnm4NYg> MoDObY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= NXWzbmpvOjR2MU[zOFk>
U2OS  NGnNR3VHfW6ldHnvckBCe3OjeR?= NE\pWIUxNjVxMX3N MmT3OFhp M3rqc4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ Mn7tNlQ{PTh|NEK=
MG-63 Mn3DSpVv[3Srb36gRZN{[Xl? Mn\3NE42NzGvTR?= MUe0PIg> Ml;wbY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NWrQT3E4OjR|NUizOFI>
MG-63 M32xbGFxd3C2b4Ppd{BCe3OjeR?= NFvZZ5kxNjVxMX3N NFK1WYo{Omh? MVTlcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NGqye4EzPDN3OEO0Ni=>
MG-63 M3z5W2Fxd3C2b4Ppd{BCe3OjeR?= MUGxNI1O NF22RYMyOmh? MYDlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NWfIfplPOjR|NUizNFE>
NTUB1 MVPBdI9xfG:|aYOgRZN{[Xl? MlHLOY1O MlTqNU42cA>? MWLwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM> NW\TUnMyOjR|NEmxO|Y>
T24 M2HaTmFxd3C2b4Ppd{BCe3OjeR?= M3:5RVVuVQ>? M4DLW|EvPWh? NXrWWG55eG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| M1P4XVI1OzR7MUe2
SGC-7901  NYTsRlVuSXCxcITvd4l{KEG|c3H5 MU[ycW0> NGjxeooycA>? MVPpcoNz\WG|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>? NEDSZlQzPDN{MUO0NC=>
SMMC-7721 NETOS3RCeG:ydH;zbZMhSXO|YYm= Ml\zNo1O NVTRbpJKOWh? NX;MdXFocW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= M1LldVI1OzJzM{Sw
ECSCs  NGm5PIFCeG:ydH;zbZMhSXO|YYm= MYexNI1O NVTK[oJwPGh? MU\k[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz M4[wO|I1OzF7MUC5
MCF-7  NGH0PFNHfW6ldHnvckBCe3OjeR?= NVTqVWRzOTCvTR?= M4fOVlI1cA>? NH21RYFqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgZ4hmdW:2aHXyZZB6KGS{dXfz M4nINlI1OzF3NUe4
UOK257 MmDrRZBweHSxc3nzJGF{e2G7 M3zRZlVuVQ>? MWqzbC=> NIq5blJmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li MmPmNlQ{ODV4MES=
ACHN-5968 NX3JVnJoSXCxcITvd4l{KEG|c3H5 M4rPO|VuVQ>? NYP4cIQ4O2h? NXjne4Zt\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= M4nseVI1OzB3NkC0
Huh7 M1z5VWFxd3C2b4Ppd{BCe3OjeR?= MWiycW0> NFnQOZEyOmh? MlPNSG1UVw>? NHXFUY9qdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> NEjlbFkzPDJ7N{OwNC=>
Hep3B NV;RVWNiSXCxcITvd4l{KEG|c3H5 MV:ycW0> MljMNVJp Mm\SSG1UVw>? NWLCd5JNcW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> NYDGUmh{OjR{OUezNFA>
RKO MmnwSpVv[3Srb36gRZN{[Xl? M17HdlJuVQ>? MVexbC=> M1fyO2ROW09? MVjlcohidmOnczDj[YxtKGSnYYToJIJ6KGenbHThcoFugWOrbh?= NVrDcFZMOjR{OUG3O|c>
HepG2 E47 M{GwfGZ2dmO2aX;uJGF{e2G7 NHnVZZMzNjWvTR?= NI\yVW01QGh? MnvabY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?= MYCyOFI4Ozd|OB?=
LoVo  MYjBdI9xfG:|aYOgRZN{[Xl? M2XQd|VuVQ>? NFPp[Jg1QGh? MlH4[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? M33vUlI1OjBzOEGy
WiDr MljvSpVv[3Srb36gRZN{[Xl? MmPvNVBuVQ>? Mlq3NYg> NV;qRXhxcW6qaXLpeJMhWEOETD3pcoR2[2WmIFzDN{BKUSCneIDy[ZN{cW:w NFjUbnczPDF7MES4PS=>
H1299  NH;aPXpHfW6ldHnvckBCe3OjeR?= M1m1XFExdU1? MUW0bC=> M4nKPIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NVzVdFh3OjRzN{OyNFg>
H460 NEPjTldHfW6ldHnvckBCe3OjeR?= NE\4e4EyOG2P NInIZ5U1cA>? NH\yfpNqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MmrTNlQyPzN{MEi=
A549 MlvmSpVv[3Srb36gRZN{[Xl? NF\qTXEyOG2P MnmwOIg> Mk[5bY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhcXK{YXTpZZRqd25? M{KxclI1OTR{N{O1
Hep3B MWLBdI9xfG:|aYOgRZN{[Xl? MoLvOY1O M3n5b|I1cA>? MkHQZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz NIjmO4EzPDB4Nk[5Ny=>
SMMC-7721 MXrBdI9xfG:|aYOgRZN{[Xl? NULQXJJSPW2P M1L0ZVI1cA>? NHnsdmhifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> M{XJVVI1ODZ4Nkmz
HO8910 NIfhSXdCeG:ydH;zbZMhSXO|YYm= Mli5NVBuVQ>? NGLiZmYyOmh? M4LTToVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq M1LNW|I{QTh|NkGw
MCF7 NWTBZnl6TnWwY4Tpc44hSXO|YYm= MlnjOY1O M1nhUVI1cA>? MVjpcoNz\WG|ZYOgR5VQKGmwZIXj[YQh[2WubDDk[YF1cA>? NWnuOVZFOjN7NkK2Nlk>
HONE-1  MYXGeY5kfGmxbjDBd5NigQ>? NGKyOlE2dU1? NH2yOm0ycA>? M4nMRZJmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=> MoHjNlM5QTJ|NUi=
HeLa NE\PSnNHfW6ldHnvckBCe3OjeR?= M1\lNlExdU1? NULsV2JmOmh? NI\kTZZ{fXCycnXzd4V{KEyFMzDJTUBmgHC{ZYPzbZNwdg>? NHXxO5QzOzh4NEezPC=>
HepG2 NXLmOWVDTnWwY4Tpc44hSXO|YYm= NGe0NJEyOG2P MY[yOIg> M3\hT4lvcGmkaYTzJJNqXEmJQWKtJIFv\CCKQmPTMYlv\HWlZXSgZZV1d3CqYXf5 NGr0dZIzOzhzN{C0NC=>
SH-SY5Y M1zGW2Z2dmO2aX;uJGF{e2G7 MUexcW0> NF;jdpQzPGh? M4\NXolvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDUU2NR MWOyN|c1OzF2OB?=
SH-SY5Y MWLBdI9xfG:|aYOgRZN{[Xl? MlWxOY1O MlnCNYg> M2rBRYFjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?= MWOyN|YyQTN7NR?=
PC12  NXK2ZXlqTnWwY4Tpc44hSXO|YYm= NW\6bG9kOTCvTR?= NYTLU4l4OjSq NWS2OI9If2G2ZYK= MUZCpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>? NIq0WVQzOzZyM{m3PS=>
OV2008 MXzBdI9xfG:|aYOgRZN{[Xl? M{XkNlVuVQ>? MVqyOIg> NHWyTIxkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= NYixUGFPOjN3OUKyPFE>
A2780 M{LHeWFxd3C2b4Ppd{BCe3OjeR?= M2n6fFVuVQ>? Mmn3NlRp MnzCZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? MkLONlM2QTJ{OEG=
Saos-2  M33Rc2Fxd3C2b4Ppd{BCe3OjeR?= MnfBNY1O MWq5Oog> NHfFfZJqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGDDXC=> NWjORpNlOjN3NkOxO|E>
1321N1 M2nw[2N6fG:2b4jpZ4l1gSCDc4PhfS=> MW[1cW0> Mne2NlRp NH7Mbo5xem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= NGrQZ20zOzV{NUK2OS=>
SH-SY5Y M{PuPWN6fG:2b4jpZ4l1gSCDc4PhfS=> Mm\OOY1O NFW3WWMzPGh? NGriS5BqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 MWCyN|UzPTJ4NR?=
HT-29  NHLBSJVHfW6ldHnvckBCe3OjeR?= NUHCVGJiOW2P M3zBc|Q5Nzl4aB?= MkH0bY5pcWKrdIOgRW1RUyCrbnT1Z4V{KGG3dH;wbIFocWNiY3XscEBl\WG2aB?= MV6yN|UxQDJ5Mh?=
OR6 M{nxVGZ2dmO2aX;uJGF{e2G7 M3nNSFExdU1? MUW3Nog> MkHrd5VxeHKnc4Pld{BJS1ZicnXwcIlk[XSrb36gZY5lKG[xcn3heIlwdiCxZjDheZRweGijZ3;zc41mew>? M1LHPVI{Ozl3OEe1
Hela  NV7KT2RpTnWwY4Tpc44hSXO|YYm= MUm1cW0> MWCyOIg> MkP5bY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> NYPCUGE{OjN|OUW2O|k>
MCF-7  NYPhcJY2TnWwY4Tpc44hSXO|YYm= MYm1cW0> M1rHZ|I1cA>? NULmfG5KcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? NGXwTnYzOzN7NU[3PS=>
HUVECs MmfCSpVv[3Srb36gRZN{[Xl? M{\PXVNuVQ>? MVKyOIg> NFK1[nljdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7 NIXreI0zOzN3OEmyPC=>
T24 MmXJSpVv[3Srb36gRZN{[Xl? M{ja[lExdU1? NIPvVHUycA>? NVvsNHdHemWmdXPld{B1cGViY3zlZZZi\2Vib3[gUGM{KGGodHXyJIJicWOjbHnuJJRz\WG2bXXueC=> Mor0NlM{PTRyOEC=
U251MG  M2XIXmZ2dmO2aX;uJGF{e2G7 NGfxd4Q{dU1? NGDQ[YUycA>? Mluwd5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u MkCwNlM{Ozh4MUi=
GTL-16  MVTBdI9xfG:|aYOgRZN{[Xl? MW[1cW0> NHrTcYEzPGh? NVr4RWp5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhd{Bkd22yYYLl[EB1dyClZXzsd{B1emWjdHXkJJdqfGhiTVXUJIlvcGmkaYTvdpM> M{Gy[|I{OzF|NEmw
T-47D MUDGeY5kfGmxbjDBd5NigQ>? MX[xNI1O NWDqRYdXOmh? M2\kSIlvcGmkaYTzJIF2fG:yaHHnfUBxem:lZYPzJIFv\CCrbnPy[YF{\XNicnHwZY16[2mwIHnu[JVk\WRiYYDvdJRwe2m| NUSwWmN6OjN|MECwNlY>
PaCa44 NE\Vc25CeG:ydH;zbZMhSXO|YYm= NWHmbFdsOi53bV2= MmqzNYg> M3LtZZJm\HWlZYRCpIdmdmmyaX6tcYVlcWG2ZXSgZZBweHSxc3nz Ml;JNlMyOjRzMUK=
MDA-MB231 NULUb5J7TnWwY4Tpc44hSXO|YYm= MYm1cW0> NUnlfWxyOWh? MnPRbY5kemWjc3XzJJJme3[ncnH0do9tNW2nZHnheIVlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> NXPlPZF7OjNyOEi4OVA>
HeLa NHTWT29CeG:ydH;zbZMhSXO|YYm= NIfoUpEyOG2P MWCybC=> M1jhRoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> NYLRTnZYOjNyMECxN|U>
SK-HEP-1 NHzQ[ndCeG:ydH;zbZMhSXO|YYm= Mn6xNVBuVQ>? MmniNYg> M3TNXJBzd3SnY4TzJIFo[Wmwc4SgZZV1d3CqYXf5JIFv\CCrbnT1Z4V{KGGyb4D0c5NqeyCrbjDieYZidGmwLYTy[YF1\WRiY3XscJM> NITt[G8zOjh3OE[0PS=>
HepG2 M1XsVWFxd3C2b4Ppd{BCe3OjeR?= M{Lod|NuVQ>? NF7lVHQ2cA>? NXfjUldOemWmdXPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHFFew>? M4Dne|IzQDN4NUm1
MCF-7  M2KzTmZ2dmO2aX;uJGF{e2G7 MV:ycW0> MVGyOIg> NU\4UmhkcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> M124UVI1QTdyNke2
MDA-MB-231 MYLGeY5kfGmxbjDBd5NigQ>? NYfMT2hHOm2P MljnNlRp MYDpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi M1jMZVI1QTdyNke2
MCF-7  NF7G[IJHfW6ldHnvckBCe3OjeR?= NGX3UWkzdU1? MUi0PIg> NGDaSplxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? MknnNlQ6PzB4N{[=
MDA-MB-231 M{DEbmZ2dmO2aX;uJGF{e2G7 NUnreJpHOm2P NUHDOJBkPDiq NGjqO2Nxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? MWeyOFk4ODZ5Nh?=
PANC-1  NXPYfFdQSXCxcITvd4l{KEG|c3H5 NH3yRXQydU1? MYi0PIg> Mn;1SG1UVw>? NEnOUXZmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? M4T4SlI1QDR{MUW4
MDA-MB 231 NVO0d5FxSXCxcITvd4l{KEG|c3H5 NFP6N|k2dU1? MXqwMlVp MlzwcY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> NUDNO|ZYOjR6M{C3PFE>
Microglia  M3[1PGFxd3C2b4Ppd{BCe3OjeR?= NXficXR{PW2P NF;rVZIzPGh? NVTEbY5Y\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRp NV3xNFU{OjR6MUi2NFE>
A2780cp Ml\HRZBweHSxc3nzJGF{e2G7 NU\kWJZWOi53bV2= NWLR[pBIOWh? MlPk[IRJOk9? M1;ibYVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NIrVcHUzPDhzN{m0Oi=>
HepG2 MX;GeY5kfGmxbjDBd5NigQ>? NH\3NFE2dU1? MmfaOIg> MX3pcoNz\WG|ZYOgZ4VtdHWuYYKgcIV3\Wy|IH;mJGhNyqB? NFfxdoYzPDdzM{W4Oy=>
U2OS NHy2Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[1WnMyOG2P Mkj0NlRp NXHqOXE6cW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhTG:6 MlyyNlQ3OzlyMUO=
HCT116 NG\Ib|dCeG:ydH;zbZMhSXO|YYm= NYj5WXhzPW2P M{DGN|I1cA>? NIX6SVlFVVOR Mor5[Y5p[W6lZYOgZZBq\2WwaX6tbY5lfWOnZDDj[YxtKGSnYYTo Mnu5NlQ3OjZ3MkK=
MCF-7  NXLlPIRUSXCxcITvd4l{KEG|c3H5 MkLCNE4ydU1? NXTPcFgzPmh? MkT4[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:|aYO= MlrJNlI4PTF7OEm=
PC-3  NXzDVXBFSXCxcITvd4l{KEG|c3H5 NEC2enozdU1? NWPrU3JXOmh? NEf1UGtqdmO{ZXHz[ZMhV1KLLXnu[JVk\WRiY3XscEBl\WG2aB?= NGHMcIMzOjd2NUW4NC=>
U251  NVe3VpJtSXCxcITvd4l{KEG|c3H5 NU\zOI1zPW2P NXzSSW5SOjSq Mk\IbY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? MlLjNlI2Pzl5OEi=
HeLa  M4HOZmFxd3C2b4Ppd{BCe3OjeR?= NHfze4U2dU1? M1L3b|I1cA>? M{fXdIlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=> MVqyNlU1PTF{OB?=
A549 NYrLRWZWTnWwY4Tpc44hSXO|YYm= NHPKc3UxNjGvTR?= MYmyOIg> NEDEUVZ{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp NH7iemwzOjR4Nkm2NC=>
pDCs MYjGeY5kfGmxbjDBd5NigQ>? NV;rUZhPOTCvTR?= NVvNO2E6OC53aB?= NHnZflDDqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> M330flIzOzl4NUm5
BGC-823 MWfGeY5kfGmxbjDBd5NigQ>? NX3LXXF[PW2P NGHrNWQzcA>? NIrMS3VqdmirYnn0d{B1cGVicnH0[UBw\iCjdYTvdIhi\2mlIHPlcIx{ MkDVNlI{OjJzNUK=
U937 NUnsNJRkTnWwY4Tpc44hSXO|YYm= MYiycW0> MnftNVJp NUT1UWh2\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= M3TVU|IzOTV3MUWw
Marc-145 MVTGeY5kfGmxbjDBd5NigQ>? M37BTlVuVQ>? MWixNk8zPC9|Nni= MmnOdoVlfWOnczD0bIUhWFKUU2[geIl1\XK|IHHu[EB1cGVicILveIVqdiCneIDy[ZN{cW:w MmPBNlIyOTl7MEC=
HBx  Mnf2RZBweHSxc3nzJGF{e2G7 M2KyWVExdU1? MYW0PIg> MWTEUXNQ MW\pcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> NVLFdFN7OjJyMkCwO|g>
MCF-7 NX[wUJc5TnWwY4Tpc44hSXO|YYm= NYXtR2tIOTCvTR?= MYS0PIg> NHjDZnBjdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? NWWyZ5hDOjF7M{G5N|c>
RMPI8226  MoTISpVv[3Srb36gRZN{[Xl? NFzIU3k2dU1? MXmxbC=> NWL2dnZNe3WycILld5NmeyC2aHWgcIV3\Wxib3[gZZV1d3CqYXf5JJVv\GW{IH71eJJq\W62IHTldIxmfGmxbh?= MUmyNVkyPTZ{MB?=
PC12/TetOn NWjyd405TnWwY4Tpc44hSXO|YYm= MWqwMlEwOW2P MYKxPIg> M2O0R4xm[WS|IITvJO6yNXO7bjjXWEkh[WOldX31cIF1cW:wLDD0c5hq[2m2eTygZY5lKG:uaXfvcYVzKG[xcn3heIlwdsLi MorjNlE6ODZ4NUm=
HeLa  M4fyOmN6fG:2b4jpZ4l1gSCDc4PhfS=> MmPqNo1O MlOyNlRp M4XmdolvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> NUW1d4tGOjF6N{WzPFU>
Jurkat M3TaVmZ2dmO2aX;uJGF{e2G7 NVHheFVDOTCvTR?= MWixbC=> M{jLT4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NYT0bYxjOjF6NkSwN|c>
K562 MWnGeY5kfGmxbjDBd5NigQ>? MnXpNVBuVQ>? MV2xbC=> NGLx[Yxl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MlX5NlE5PjRyM{e=
Nara-H MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTNOY1O NEHlNGM1QGh? MnS3[Y5p[W6lZYOgeIVue2m{b3zpcZV{dWWmaXH0[YQhe3WycILld5Nqd25ib3[gUoFz[S2KIHPlcIwheHKxbHnm[ZJifGmxbh?= M3P5OFIyQDB3MEOz
HUVECs M4LIemZ2dmO2aX;uJGF{e2G7 MWGxNI1O NF:w[pkxNjWq M{P5bYRm[3KnYYPld{B1cGViQVfFMWJUSWmwZIXj[YQh[XW2b4DoZYd6KGyndnW= M3Pse|IyPDZ6NUmy
HepG2 NXznfm9XSXCxcITvd4l{KEG|c3H5 NHr2[nUzdU1? MorjNYg> MlPD[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmrzNlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
DMSO 3 mg/mL warmed (20.11 mM)
Ethanol '4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389
Smiles C[N]1C=NC(=C2N=CN=C12)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID